• Over the past six months, Globus Medical has reported strong constant currency revenue growth averaging 22.3% year-on-year, reflecting rapid global expansion but accompanied by a declining return on invested capital that raises questions about the profitability of this growth.
• In early May 2026, the company also reported its first-quarter 2026 results and held an investor call, an event that is now past but remains important as investors weigh whether rapid top-line momentum can be balanced with improving capital efficiency.
• Against this backdrop of rapid revenue expansion, we’ll now examine how the recent results and upcoming earnings discussion reshape Globus Medical’s investment narrative.

Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

Globus Medical Investment Narrative Recap

To own Globus Medical, you need to believe its musculoskeletal and robotics portfolio can translate strong revenue growth into sustainably attractive returns, despite a recent decline in ROIC. The key near term catalyst is how upcoming earnings and commentary address the balance between rapid top line expansion and capital efficiency. The latest update on Q1 2026 timing does not materially change that equation, but it focuses attention on whether recent momentum is coming through profitably.

The most relevant recent announcement is Globus reaffirming full year 2026 revenue guidance of US$3.18 billion to US$3.22 billion alongside strong 2025 results. That commitment anchors expectations ahead of the Q1 2026 release and puts more scrutiny on margins, integration progress and ROIC trends. For investors, the question is less about growth existing and more about how efficiently that growth is being converted into earnings and cash flow.

Yet beneath the strong growth story, investors should be aware of the pressure that a declining return on invested capital could eventually place on...

Globus Medical's narrative projects $3.6 billion revenue and $624.6 million earnings by 2029.

Uncover how Globus Medical's forecasts yield a $110.08 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were framing Globus as a margin expansion story, expecting earnings of about US$631 million by 2029 and potentially higher revenue if robotics adoption and cost actions outperformed. Compared with the consensus focus on steady growth and integration risk, this view leaned on faster operating leverage and aggressive efficiency gains that may now be reassessed in light of how current ROIC trends evolve from here.

Explore 5 other fair value estimates on Globus Medical - why the stock might be worth as much as 16% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Globus Medical research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.